Form 4: Foghorn Therapeutics CFO Kristian Humer Acquires Stock Options

Kristian Humer, CFO of Foghorn Therapeutics, reports the acquisition of stock options.

Summary

• Kristian Humer, the Chief Financial Officer of Foghorn Therapeutics Inc. (FHTX), acquired stock options on April 16, 2024.
• The transaction involved the acquisition of options to purchase 275,000 shares of common stock at an exercise price of $6.03 per share.
• The options vest as to 25% of the underlying shares on April 16, 2025, and then at a rate of 6.25% per quarter until fully vested.
• Following the transaction, Humer beneficially owns 275,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants, which is neither particularly positive nor negative on its own. The CFO acquiring options is a good sign, but it's expected.

Positives

• The CFO's acquisition of stock options could be seen as a positive signal, indicating confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, reflecting a common practice of granting stock options to company executives as part of their compensation package. It's typical for biotech companies to use stock options to incentivize their leadership.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for executives in the biotechnology industry.
• Companies like Amgen, Gilead, and Biogen routinely grant stock options to their executives.
• The vesting schedule of 25% after one year followed by quarterly vesting is also a fairly standard practice.

Stakeholder Impact

• The acquisition of stock options by the CFO could have a slightly positive impact on shareholder sentiment, as it aligns the CFO's interests with those of the shareholders.

Key Dates